当前位置:

网站首页>文章详情

瑞舒伐他汀对比阿托伐他汀的药物经济学评价

【PDF在线阅读】 【下载PDF】
  • Author:

  • Author Unit:

  • Keywords:

摘要:

目的 了解瑞舒伐他汀与阿托伐他汀在治疗血脂异常方面国内外使用的成本分析方法和二
者的经济性,以期为临床选择具有药物经济学优势的药物提供参考依据。方法 以国内外现已公开发表
的瑞舒伐他汀对比阿托伐他汀治疗血脂异常的药物经济学评价文献为研究对象,对文献进行归纳分类并
总结分析。结果 最终纳入30篇文献,英文23篇,中文7篇。尽管采用不同的成本分析方法,多数研究表
明瑞舒伐他汀的成本-效果/效用更优。结论 与阿托伐他汀相比,瑞舒伐他汀在治疗血脂异常方面更具有
药物经济学优势,更能提高患者的生存质量。

Abstract:

Objectives To understand the cost analysis methods and economics of rosuvastatin and atorvastatin
in the treatment of dyslipidemia at home and abroad, and to provide a reference for clinical selection of drugs with
pharmacoeconomic advantages. Methods Taking the rosuvastatin and atorvastatin pharmacoeconomic evaluation
literatures published at domestic and abroad as research objects, the literatures were classified and summarized. Results
Finally, 30 articles were included, 23 in English and 7 in Chinese. Despite different cost analysis methods, most studies
show better cost-effectiveness/utility of rosuvastatin. Conclusion Compared with atorvastatin, rosuvastatin has more
pharmacoeconomic advantages in treating dyslipidemia and can improve the quality of life of patients.

基金项目:

参考文献:

[1] ALLHAT Officers and Coordinators for the ALLHAT Collaborative.
Research Group. The antihypertensive and lipid-lowering
treatment to prevent heart attack trial. Major outcomes in highrisk
hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium channel blocker vs diuretic: the
antihypertensive and lipid-lowering treatment to prevent heart attack
trial (ALLHAT)[J]. JAMA,2002,288(23):2981-97.
[2] Lee SH,Kwon HS,Park YM,et al. Statin discontinuation after achieving
a target low density lipoprotein cholesterol level in type 2 diabetic
patients without cardiovascular disease: a randomized controlled
study[J]. Diabetes Metab J,2014,38(1):64-73.
[3] Nissen SE,Nicholls SJ,Sipahi I,et al. Effect of very high-intensity
statin therapy on regression of coronary atherosclerosis: the
ASTEROID trial[J]. JAMA, 2006, 295(13):1556-65.
[4] Nissen SE,Tuzcu EM,Schoenhagen P,et al. Effect of intensive
compared with moderate lipid-lowering therapy on progression of
coronary atherosclerosis: a randomized controlled trial[J]. JAMA,
2004,291(9):1071-80.
[5] Kim HS,Lee H,Park B,et al. Comparative analysis of the efficacy of
low- and moderate-intensity statins in Korea[J]. Int J Clin Pharmacol
Ther, 2016, 54(11):864-71.
[6] Maron DJ,Fazio S,Linton MF. Current perspectives on statins[J]. Circul
ation,2000,101(2):207-13.
[7] 钱彦华,蒋潇,方甜甜,等. 3种他汀类药物治疗冠心病的成本-效果
分析[J]. 海峡药学,2014,(9):146-8.
[8] 吴飞跃,贝金币. 绝经后妇女原发性高脂血症4种治疗方案的疗效
及成本-效果分析[J]. 药物流行病学杂志,2014,(2):108-11.
[9] 王泽,王雷. 两种方案治疗冠心病的疗效及药物经济学评价[J]. 中
国药物与临床,2017,17(1):101-3.
[10] 郭胜红,汪延安,孙文武,等. 两种中等强度他汀类药物方案治疗高
脂血症的成本-效果分析[J]. 中国药房,2017,28(26):3610-3.
[11] 梁宇锋,李松,韦国麟. 瑞舒伐他汀和阿托伐他汀治疗动脉粥
样硬化性脑梗死伴高脂血症的成本-效果分析[J]. 吉林医学,
2015(18):4053-4.
[12] 李莉,LILi. 瑞舒伐他汀与阿托伐他汀在冠心病调脂治疗中的药
物经济学比较[J]. 海峡药学,2015,27(10):271-3.
[13] 王宇,徐颖颖,张相彩,等. 他汀类药物的经济学研究[J]. 中国现代
应用药学,2015,32(9):1134-8.
[14] Palmer SJ,Brady AJ,Ratcliffe AE. The cost-effectiveness of a new
statin (rosuvastatin) in the UK NHS[J]. International Journal of
Clinical Practice,2003,57(9):792.
[15] Hirsch M,O'Donnell JC,Jones P. Rosuvastatin is cost-effective
in treating patients to low-density lipoprotein-cholesterol goals
compared with atorvastatin, pravastatin and simvastatin: analysis of
the STELLAR trial[J]. European journal of cardiovascular prevention
and rehabilitation: official journal of the European Society of
Cardiology, Working Groups on Epidemiology & Prevention and
Cardiac Rehabilitation and Exercise Physiology,2005,12(1):18-28.

[16] Hirsch M,O'Donnell J,Olsson A. Rosuvastatin is cost-effective

compared with atorvastatin in reaching cholesterol goals[J].
International Journal of Cardiology,2005,104(3):251.
[17] Ara R,Pandor A,Stevens J,et al. Early high-dose lipid-lowering
therapy to avoid cardiac events: a systematic review and economic
evaluation[J]. Health Technology Assessment,2009,13(34):1-74,
75-118.
[18] Ara R,Pandor A,Stevens J,et al. Prescribing high-dose lipid-lowering
therapy early to avoid subsequent cardiovascular events: is this a costeffective
strategy?[J]. European Journal of Preventive Cardiology,2012,
19(3):474-83.
[19] Benner JS,Smith TW,Klingman D,et al. Cost-effectiveness of
rosuvastatin compared with other statins from a managed care
perspective[J]. Value in Health,2010,8(6):618-28.
[20] Chong PH,Varner D. Cost-efficacy analysis of 3-hydroxy-3-
methylglutaryl coenzyme a reductase inhibitors based on results of
the STELLAR trial: clinical implications for therapeutic selection[J].
Pharmacotherapy,2005,25(2):270.
[21] Miller PSJ,Smith DG,Jones P. Cost Effectiveness of Rosuvastatin,
in Treating Patients to Low-Density Lipoprotein Cholesterol Goals
Compared With Atorvastatin, Pravastatin, and Simvastatin, (a US
Analysis of the STELLAR Trial)[J]. American Journal of Cardiology,
2005,95(11):1314-9.
[22] Ohsfeldt RL,Gandhi SK,Fox KM,et al. Statin Cost-Effectiveness
Comparisons Using Real-World Effectiveness Data: Formulary
Implications[J]. Value in Health,2008,11(7):1061-9.
[23] Montouchet C,Ruff L,Balu S. Budget impact of rosuvastatin initiation
in high-risk hyperlipidemic patients from a US managed care
perspective[J]. Journal of Medical Economics,2013,16(7):907-16.
[24] Plans-Rubió DP. The Cost Effectiveness of Statin Therapies in Spain
in 2010, after the Introduction of Generics and Reference Prices[J].
American Journal of Cardiovascular Drugs,2010, 10(6):369-82.
[25] Barrios V,Lobos JM,Serrano A,et al. Cost-effectiveness analysis of
rosuvastatin vs generic atorvastatin in Spain[J]. Journal of Medical
Economics,2012,15(sup1):45-54.
[26] Cosin SJ,Fuentes Jiménez FJ,Mantilla MT,et al. Cost-effectiveness
of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in
patients with high and very high cardiovascular risk in Spain[J]. Clin
Investig Arterioscler,2015,27(5):228-38.
[27] Tran YB,Frial T,Miller PS. Statin's cost-effectiveness: a Canadian
analysis of commonly prescribed generic and brand name statins[J].
Can J Clin Pharmacol,2007,14(2):e205.
[28] Costascharplatz M,Ramanathan K,Frial T,et al. Cost-effectiveness
analysis of rosuvastatin versus atorvastatin, simvastatin, and
pravastatin from a Canadian health system perspective[J]. Clinical
Therapeutics, 2008, 30(7):1345-1357.
[29] Peura P,Martikainen J,Soini E,et al. Cost-effectiveness of statins
in the prevention of coronary heart disease events in middle-aged
Finnish men. Curr Med Res Opin,2008,24(6):1823-32.
[30] Pinto CG,Carrageta MO,Miguel LS. Cost-Effectiveness of Rosuvastatin
in the Prevention of Ischemic Heart Disease in Portugal[J]. Value in
Health,2008,11(2):154-9.
[31] Laires PA,Ejzykowicz F,Hsu TY,et al. Cost-effectiveness of adding
ezetimibe to atorvastatin versus switching to rosuvastatin therapy in
Portugal.[J]. Journal of Medical Economics,2015,18(8):565-72.
[32] Gandhi SK,Jensen MM,Fox KM,et al. Cost-effectiveness of
rosuvastatin in comparison with generic atorvastatin and simvastatin
in a Swedish population at high risk of cardiovascular events[J].
Clinicoeconomics & Outcomes Research Ceor,2012,4:1-11.
[33] Fragoulakis V,Kourlaba G,Maniadakis N. Economic evaluation of
statins in high-risk patients treated for primary and secondary
prevention of cardiovascular disease in Greece[J]. Clinicoecon
Outcomes Res,2012,4:135-43.
[34] Ribeiro RA,Duncan BB,Ziegelmann PK,et al. Cost-Effectiveness of
High, Moderate and Low-Dose Statins in thePrevention of Vascular
Events in the Brazilian Public Health System[J]. Arquivos Brasileiros
De Cardiologia,2015,104(1):32-43.
[35] Jeong YJ,Kim H,Baik SJ,et al. Analysis and comparison of the
cost-effectiveness of statins according to the baseline low-density
lipoprotein cholesterol level in Korea[J]. Journal of Clinical Pharmacy
& Therapeutics, 2017, 42(3):292.
[36] Ohsfeldt RL,Gandhi SK,Fox KM,et al. Effectiveness and costeffectiveness
of rosuvastatin, atorvastatin, and simvastatin among
high-risk patients in usual clinical practice[J]. American Journal of
Managed Care,2006,12(15 Suppl):S412-23.
[37] Soran H and Durrington P. Rosuvastatin: efficacy, safety and clinical
effectiveness[J]. Expert Opin Pharmacother,2008,9(12):1-16.
[38] 赵铁夫,王盛宇,陈宏,等. 瑞舒伐他汀和阿托伐他汀对非体外
循环冠状动脉旁路移植术后患者降脂效果的比较[J]. 中国医
药,2017,12(6):834-7.

  • 2008

  • 1

通讯地址:北京市东城区东四十条南门仓5号
电话: 237499284 邮编:100700
网址:www.ebcvm..org Email: ebcvm_cj@126.com

copyright © 《中国循证心血管医学杂志》编辑部
当您在使用本网站投稿遇到困难时,
请直接将稿件投送到编辑部邮箱ebcvm_cj@126.com